Upregulation of lncRNA NR_046683 serves as a prognostic biomarker and potential drug target for multiple myeloma

14Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Aim: To investigate the prognostic value of lncRNA NR_046683 in multiple myeloma (MM). Methods: High-throughput lncRNA array was combined with bioinformatics techniques to screen differentially expressed lncRNA in MM. qRT-PCR was adopted to determine the expression of target lncRNAs in MM patients and controls. Results: It was found for the first time that lncRNA NR_046683 is closely related to the prognosis of MM. It was also detected in tumor cell lines KM3, U266, especially in drug-resistant cell lines KM3/BTZ and MM1R. The NR_046683 expression differed significantly in patients of different MM subtypes and staging. Moreover, the overexpression of NR-046683 is closely related to β2-microglobulin. We also found that the overexpression of NR-046683 correlates to chromosomal aberrations, such as del(13q14), gain 1q21, and t(4;14). Conclusion: lncRNA NR_046683 can serve as a novel biomarker for potential drug target and prognostic prediction in MM.

Cite

CITATION STYLE

APA

Dong, H., Jiang, S., Fu, Y., Luo, Y., Gui, R., & Liu, J. (2019). Upregulation of lncRNA NR_046683 serves as a prognostic biomarker and potential drug target for multiple myeloma. Frontiers in Pharmacology, 9(JAN). https://doi.org/10.3389/fphar.2019.00045

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free